Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Open-Label, Single-Arm, Non-Randomized, Single-Dose, Dose-Escalation Investigator-Initiated Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NKG001 Injection in Patients With Type 1 or Type 2 Spinal Muscular Atrophy

NCT07617779 is registered in ClinicalTrials.gov with Nikegen Pharmaceutical (Hangzhou) Company Limited as lead sponsor.

NCT NCT07617779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07617779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Open-Label, Single-Arm, Non-Randomized, Single-Dose, Dose-Escalation Investigator-Initiated Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NKG001 Injection in Patients With Type 1 or Type 2 Spinal Muscular Atrophy
Lead sponsor
Nikegen Pharmaceutical (Hangzhou) Company Limited
Phase
Not applicable
Overall status
Active, not recruiting
Start date
April 21, 2024
Completion date
April 23, 2030
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy (sma)